Becton Dickinson Q1 Revenue Seen Flat at $5.15B, Adjusted EPS $2.81
Becton Dickinson posted Q4 revenue of $5.89B, up 8.3% y/y, with EPS narrowly beating estimates. Analysts expect Q1 revenue to remain flat at $5.15B with $2.81 adjusted EPS, while peers STERIS and CONMED saw 9.2% and 7.9% revenue growth but share price declines post-results.
1. Q4 Results Recap
Becton Dickinson posted Q4 revenue of $5.89 billion, matching analysts’ estimates and up 8.3% year-over-year, while adjusted EPS narrowly beat consensus. The company has missed Wall Street’s revenue estimates four times over the past two years, reflecting execution challenges in certain segments.
2. Q1 Expectations
Analysts forecast Q1 revenue of $5.15 billion, flat year-over-year compared with 9.8% growth in the same period last year, and adjusted EPS of $2.81 per share. Consensus estimates have remained stable over the past 30 days, indicating subdued expectations for the company’s near-term growth trajectory.
3. Peers’ Performance
In the healthcare equipment and supplies segment, STERIS reported 9.2% year-over-year revenue growth and CONMED 7.9%, yet both stocks fell 7.7% and 3.6% respectively following their Q4 disclosures. Market reactions highlight investor scrutiny on margins and forward guidance despite top-line strength.
4. Stock Movement and Analyst Targets
Becton Dickinson shares have climbed 3.6% over the past month while the sector index declined 3.2%, reflecting relative resilience ahead of earnings. The stock trades at $206.89 versus an average analyst price target of $211.92, suggesting modest upside according to broker forecasts.